Next, the KEYNOTE-789 trial randomized 492 patients with EGFR-mutated NSCLC and progression after TKI treatment 1:1 to receive pembrolizumab plus chemotherapy or chemotherapy alone. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.